Neurim Pharmaceuticals is a drug discovery and development company with a rich pipeline of products primarily focusing on CNS disorders.

Our small, but highly effective R&D team - located in Tel Aviv - consists of professionals with a high level of scientific expertise and has achieved remarkable drug discovery successes.

The business development unit - located in Switzerland - is comprised of professionals with first hand business experience in pharmaceutical R&D management.

What gives us a competitive advantage in drug discovery and development is our strong scientific network, the unique complementary team structure and competent executive and operating processes, aided by a lean internal infrastructure.

Neurim Pharmaceuticals has a strong intellectual property position with more than 60 patents granted and ten more pending, and a great potential with 3 pipeline products that are new chemical entities (NCEs) and protected by substance patents.

Neurim Pharmaceuticals' business strategy is to (1) discover and develop new drugs in a time and cost-effective manner up to and including drug approval, and to license out against upfront milestones and royalty payments or (2) carry out technology transfer in view of co-development of small chemical molecules.

Neurim Pharmaceuticals gains revenues from reimbursement of research and development, milestone payments, royalties, and retained manufacturing rights with reputable marketing and distribution partners.

At present, Neurim Pharmaceuticals is a privately held Company.